JP2024508334A - 家族性高カイロミクロン血症症候群を治療するための方法 - Google Patents

家族性高カイロミクロン血症症候群を治療するための方法 Download PDF

Info

Publication number
JP2024508334A
JP2024508334A JP2023553354A JP2023553354A JP2024508334A JP 2024508334 A JP2024508334 A JP 2024508334A JP 2023553354 A JP2023553354 A JP 2023553354A JP 2023553354 A JP2023553354 A JP 2023553354A JP 2024508334 A JP2024508334 A JP 2024508334A
Authority
JP
Japan
Prior art keywords
patient
lomitapide
dosing period
dose
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023553354A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508334A5 (https=
Inventor
マーク・スメレイ
Original Assignee
アムリット・ファーマシューティカルズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムリット・ファーマシューティカルズ・インコーポレイテッド filed Critical アムリット・ファーマシューティカルズ・インコーポレイテッド
Publication of JP2024508334A publication Critical patent/JP2024508334A/ja
Publication of JP2024508334A5 publication Critical patent/JP2024508334A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023553354A 2021-03-03 2022-03-03 家族性高カイロミクロン血症症候群を治療するための方法 Pending JP2024508334A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163155960P 2021-03-03 2021-03-03
US63/155,960 2021-03-03
US202163165457P 2021-03-24 2021-03-24
US63/165,457 2021-03-24
PCT/US2022/018672 WO2022187463A1 (en) 2021-03-03 2022-03-03 Methods for treating familial chylomicronemia syndrome

Publications (2)

Publication Number Publication Date
JP2024508334A true JP2024508334A (ja) 2024-02-26
JP2024508334A5 JP2024508334A5 (https=) 2025-03-06

Family

ID=80819670

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023553354A Pending JP2024508334A (ja) 2021-03-03 2022-03-03 家族性高カイロミクロン血症症候群を治療するための方法

Country Status (10)

Country Link
US (1) US20240165093A1 (https=)
EP (1) EP4301361A1 (https=)
JP (1) JP2024508334A (https=)
KR (1) KR20230153375A (https=)
AU (1) AU2022231007A1 (https=)
BR (1) BR112023016943A2 (https=)
CA (1) CA3208189A1 (https=)
IL (1) IL305191A (https=)
MX (1) MX2023010297A (https=)
WO (1) WO2022187463A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3186856A1 (en) 2020-07-29 2022-02-03 Ruth NALLEN Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007527433A (ja) * 2004-03-05 2007-09-27 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 高脂血症および高コレステロール血症に関連する障害または疾患を、副作用を最小限にしつつ処置するための方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
BR102015025502B1 (pt) 2015-04-30 2022-06-21 Aegerion Pharmaceuticals, Inc Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007527433A (ja) * 2004-03-05 2007-09-27 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 高脂血症および高コレステロール血症に関連する障害または疾患を、副作用を最小限にしつつ処置するための方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BEN-OMRAN TAWFEG; ET AL: "REAL-WORLD OUTCOMES WITH LOMITAPIDE USE IN PAEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL 以下備考", ADVANCES IN THERAPY, vol. VOL:36,NR:7, JPN5024001849, 17 May 2019 (2019-05-17), US, pages 1786 - 1811, ISSN: 0005787827 *
CEFALU ANGELO B ET AL: "EFFECTIVENESS AND SAFETY OF LOMITAPIDE IN A PATIENT WITH FAMILIAL CHYLOMICRONEMIA SYNDROME", ENDOCRINE, vol. VOL.71, NR.2, JPN5024010433, 2 October 2020 (2020-10-02), pages 344 - 350, ISSN: 0005787826 *
UNDERBERG, JAMES A. ET AL.: ""Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterole", JOURNAL OF CLINICAL LIPIDOLOGY, vol. 14, no. 6, JPN6026003271, November 2020 (2020-11-01), pages 807 - 817, ISSN: 0005787828 *

Also Published As

Publication number Publication date
IL305191A (en) 2023-10-01
BR112023016943A2 (pt) 2023-10-31
US20240165093A1 (en) 2024-05-23
AU2022231007A9 (en) 2024-09-19
AU2022231007A1 (en) 2023-08-17
KR20230153375A (ko) 2023-11-06
MX2023010297A (es) 2023-09-12
CA3208189A1 (en) 2022-09-09
EP4301361A1 (en) 2024-01-10
WO2022187463A1 (en) 2022-09-09

Similar Documents

Publication Publication Date Title
US20220152053A1 (en) Methods and compositions for treating various disorders
US11185519B2 (en) Methods of treatment of cholestatic diseases
TWI667025B (zh) 治療肝臟疾病之方法
KR20200010320A (ko) 치료 방법
CN110191724A (zh) 纤维化的治疗
WO2015053379A1 (en) Compositions and methods for treating non-alcoholic steatohepatitis
CN105764498A (zh) 纯合家族型高胆固醇血症的治疗
US20240189311A1 (en) Combination Therapy of Obicetrapib and Ezetimibe for Use in Statin Intolerant Patients Suffering from Hyperlipidemia or Mixed Dyslipidaemia
RU2485945C2 (ru) Способ лечения воспалительных заболеваний кишечника
US20220047678A1 (en) Combination Therapy for Treatment of Liver Disease
KR20150119227A (ko) 라퀴니모드에 의한 다발성 경화증의 진행형 형태의 치료
CA2959488C (en) Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and hmg coa reductase inhibitors
KR102177304B1 (ko) 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
JP2024508334A (ja) 家族性高カイロミクロン血症症候群を治療するための方法
RU2857392C2 (ru) Способы лечения синдрома семейной хиломикронемии
KR20080091824A (ko) 메글리티니드류를 함유하는 간 섬유화 예방용 의약 조성물
AU2019376907B2 (en) Treatment and inhibition of fibrosis in non-alcoholic fatty liver disease patients
WO2025224044A1 (en) Methods of treatment of primary biliary cholangitis
JP2026500731A (ja) 医薬組合せおよび医薬組成物、ならびにその使用方法
TW202612725A (zh) 用於治療代謝性脂肪性肝炎(mash)及肝硬化之雙重glp-1及升糖素受體促效劑
WO2025040345A1 (en) Elafibranor for use in the treatment of primary biliary cholangitis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250225

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203